Brokerages expect OpGen Inc (NASDAQ:OPGN) to announce earnings of ($1.38) per share for the current quarter, according to Zacks. Two analysts have provided estimates for OpGen’s earnings, with the lowest EPS estimate coming in at ($1.50) and the highest estimate coming in at ($1.25). OpGen reported earnings of ($5.25) per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 73.7%. The company is scheduled to announce its next quarterly earnings results on Thursday, March 22nd.

According to Zacks, analysts expect that OpGen will report full year earnings of ($10.25) per share for the current year. For the next fiscal year, analysts expect that the firm will post earnings of ($3.75) per share. Zacks’ EPS calculations are an average based on a survey of research analysts that cover OpGen.

OpGen (NASDAQ:OPGN) last posted its quarterly earnings data on Tuesday, November 7th. The medical research company reported ($1.75) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.00) by $0.25. OpGen had a negative net margin of 533.47% and a negative return on equity of 1,289.51%.

Several research firms have recently issued reports on OPGN. Zacks Investment Research cut shares of OpGen from a “buy” rating to a “hold” rating in a report on Wednesday, January 10th. ValuEngine upgraded shares of OpGen from a “strong sell” rating to a “sell” rating in a report on Friday. Finally, HC Wainwright reiterated a “buy” rating and issued a $25.00 price objective on shares of OpGen in a report on Wednesday, November 8th.

OpGen (NASDAQ OPGN) traded down $0.24 during trading on Tuesday, hitting $2.51. 229,076 shares of the stock traded hands, compared to its average volume of 510,907. The company has a quick ratio of 1.13, a current ratio of 1.23 and a debt-to-equity ratio of 0.03. The company has a market capitalization of $6.68, a PE ratio of -0.16 and a beta of 0.71. OpGen has a twelve month low of $2.50 and a twelve month high of $32.50.

A hedge fund recently raised its stake in OpGen stock. Vanguard Group Inc. lifted its position in OpGen Inc (NASDAQ:OPGN) by 1.6% in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 342,860 shares of the medical research company’s stock after acquiring an additional 5,500 shares during the quarter. Vanguard Group Inc. owned approximately 1.25% of OpGen worth $219,000 as of its most recent filing with the SEC.

TRADEMARK VIOLATION WARNING: This article was first posted by Daily Political and is owned by of Daily Political. If you are viewing this article on another domain, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The original version of this article can be viewed at

OpGen Company Profile

OpGen, Inc (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms.

Get a free copy of the Zacks research report on OpGen (OPGN)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with's FREE daily email newsletter.